Pefloxacin
Therapeutic agent (verify pharmacological class)
What it is used for
Severe infection in adults due to Staphylococcus and Gram-negative bacilli. Clinical selection for Pefloxacin should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: Therapeutic agent (verify pharmacological class). Confirm site-specific dose, duration and monitoring before prescribing.
Warnings
Quinolones should be used with caution in children with a history of epilepsy or conditions that predispose to seizures, in G6PD deficiency, myasthenia gravis (risk of exacerbation). Exposure to excessive sunlight should be avoided (discontinue if photosensitivity occurs). Quinolones may induce convulsions in patients with or without a history of convulsions; taking NSAIDs at the same time may also induce them. May cause arthropathy in the weight-bearing joints of immature animals and are therefore generally not recommended in children and growing adolescents. However, the significance of this effect in humans is uncertain and in some specific circumstances short-term use of a quinolone in children is justified. Should be avoid in pregnancy and lactation.
Possible side effects
Flatulence, pain and phlebitis at injection site; rarely dysphagia, pancreatitis, chest pain, tachycardia, syncope, oedema, hot flushes, abnormal dreams, sweating, hyperglycaemia, and erythema nodosum; very rarely movement disorders, tinnitus, vasculitis, and tenosynovitis.
Storage
Store as labelled. Keep out of reach of children.
No reviewed patient-education article is available. The fields shown are from the currently verified medicine record and unavailable fields are not inferred.